TCA Cellular Therapy is currently seeking strategic partnerships with other professionals devoted to the advancement of stem cell therapies.  To learn about learn more about becoming part of our innovative company please e-mail vicki@tcacellulartherapy.com.

Overview

TCA Cellular Therapy, LLC (TCA Cellular) is a biotechnology, research and development company that intends to invent, develop, patent, and market cellular therapy products for medical applications.  An autologous combination stem cell product has been developed for regenerative medicine therapy.

TCA Cellular Therapy also owns controlling interest in LifeSource Cryobank, LLC, a company specializing in the cryopreservation of umbilical cord blood and other adult stem cells.

Mission

Our mission is to create and accelerate stem cell therapies and to develop next generation medicines for serious and life-threatening diseases.  We commit ourselves to high standards of integrity in contributing to the best interests of patients, the medical profession, our employees and our communities.

Corporate Strategy

To have a world-renowned, cutting edge research and service related company that is a leader in the emerging field of stem cell therapy. We believe that regenerative medicine has the potential to revolutionize medicine by being able to produce human cells for use in a wide-array of novel and important therapies. The company is focused on being the first to commercialize the most profitable application of regenerative medicine.

Product and Accomplishments

We are currently conducting Investigator initiated clinical trials with autologous combination stem cell therapy (MESENDO).  We currently hold four IND's with the FDA:  13139, 11643, 13562 and 13729.  Our studies include therapies for patients with critical limb ischemia, coronary artery disease, myocardial infarction and ALS (Lou Gehrig's Disease).

Phase I for Critical Leg Ischemia is complete and Phase II is currently enrolling.  Phase I for severe coronary ischemia is complete and Phase II has been submitted to the FDA to begin enrollment in approximately 2 months.  Phase I, MI/CABG is currently enrolling.  Our first neurological disease treatment for ALS is currently being reviewed by the FDA.

Laboratory

TCA Cellular constructed an ISO-7, Class 10,000 GMP (Good Manufacturing Practice) laboratory, on site, for stem cell processing and/or expansion.  Our ownership of LifeSource Cryobank also gives us the opportunity to cryopreserve expanded cells for regenerative medicine purposes.

Management

Gabriel P. Lasala, MD, FACC, CEO

Jose J. Minguell, PhD, Sci